“The existing circumstance has exposed some structural weaknesses during the EU’s medicines provide chain as well as a higher dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides claimed. She advised that supply chain troubles be dealt with in an EU pharmaceutical approach envisioned for being introduced by the ti